Answers are grounded in this paper and cite their sources.
Demonstrates targeted inhibition of MRSA growth using chimeric antisense oligonucleotides, suggesting a novel antibacterial strategy.
, which lacks the FMN riboswitch, confirming specificity. Cytotoxicity testing in human A549 cells revealed 95% viability at the highest concentration. These results demonstrate that riboswitch-targeted ASOs can selectively inhibit MRSA growth with minimal toxicity, supporting their potential as a new class of antibacterial agents against drug-resistant pathogens.
No takes yet. Share an insight, caveat, or question.
Dyakova et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: